about
Acute renal failure caused by indinavir in a patient with a single functioning kidneyClinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study.Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection.Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection.Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients.Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season.Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients.Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave.Influenza A H1N1/2009 infection in pediatric solid organ transplant recipients.Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease.The impact of influenza A(H1N1)pdm09 infection on immunosuppressed patients.Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients.Community-acquired pneumonia during the first post-pandemic influenza season: a prospective, multicentre cohort study.Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.Severe acute hepatitis and cold agglutinin-related hemolytic anemia secondary to prime infection with Epstein-Barr virus.Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial.New information about the polymyxin/colistin class of antibiotics.GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.Influenza vaccination in solid-organ transplant recipients.Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical MicrManagement of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) anManagement of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMCInfluenza and other respiratory virus infections in solid organ transplant recipients.Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation.Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study.Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbitsQ fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain.First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment.Impact of HIV on the severity of influenza.Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation.CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial.Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance.Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors.Empirical antifungal therapy in selected patients with persistent febrile neutropenia.
P50
Q28369662-EA5F3073-1EC7-49EE-8B7F-000121122CD5Q30393444-39B331FB-281C-4EA8-B279-EE3941745918Q30399360-BD8C6DF9-C2E8-48A8-8D48-2C596DD3FC00Q30405250-0647DD6B-9A14-4E33-9B39-0E9D1CC33A44Q30405260-B5FCD3CE-95BC-4609-8908-A64E86745C2EQ30405856-9537E78D-407A-4F44-B68C-F89B5B4964F8Q30412062-9C5964D7-BCAA-47A8-9B21-B12B05853B9AQ30413662-F2EA4B52-7D78-4CC7-92FB-F8D6F47B4CF6Q30419507-3562D596-6994-4E38-9CD7-D903E77CAFA4Q30421504-B81AF57E-1BDC-454E-A6C1-63CF76E42F7DQ30422526-44A1A0ED-FB49-4B5E-BCB4-A05F7A324C94Q30423104-F29AD16F-8193-4F57-9A8E-F1FAEA2BDE2AQ30430823-A37E4DC1-7A23-40BB-A8A8-8770D4267D1DQ30431627-E62E7AD4-1238-4EBA-9010-5BDA5E637A75Q33386028-D9D35811-A17C-46E7-879E-07E811656929Q33440674-AF55D316-CFDC-4A19-A09F-63C73F853A2AQ34157089-40996DAE-A6C8-4F40-A404-8E82A96441A3Q37636150-F6FFC6C3-AF11-4D34-8EE3-9AC239B9BD3BQ37934102-16EC2305-08CB-4588-806E-3870563EE272Q38050048-EBDC85DB-7221-462F-B0DD-A33F88BE58AEQ38081351-46CBC016-DE0D-4B05-A90C-A0E72F292A3FQ38092937-3A6F8DFA-6792-447D-BEC6-640CCFEF8FE3Q38092938-DEEEBC9E-8343-4407-926B-9D55388E58B6Q38481763-C5891153-F6E6-4209-933A-A0E0BFC42C9EQ38602985-FD96C880-7385-45A6-9CA4-67B31B00867AQ38623310-65901BB8-FDCB-475F-BD74-930F65FC2A13Q38790699-CC71404F-2A00-4B3A-8BF2-5E8FAD937177Q38822159-A977E1B4-6F25-4EC5-9A50-0FEED88183DDQ38947867-43FCBD41-9D33-46BE-AB4F-CD398F885BF8Q38948724-20DA24CE-FE5F-4CB8-AC84-F33A3C29959BQ39473244-647F0D30-8644-47EF-8D8D-822AE0038F98Q39654913-949F992E-EE80-4732-89A6-65BFC33B424CQ39659062-CA9588B2-3506-4C7C-89CD-C99F1C2DC51DQ39966481-CB180F94-1C6B-4D4C-88F1-0756CC8519D7Q40157393-02902DAF-E006-4C83-B5E1-D8C98FAC0BCDQ40165560-CC20741B-416F-429C-A294-5C8DD199FE22Q40270352-BDC7744F-6E11-436B-90AB-60F99FDE6134Q40271648-A76A1D85-B3AA-4CD8-AB18-DEEA76B58172Q40290980-F19591CE-CA8A-4FB5-9DBA-550387308C6CQ40387020-D575B0C5-15DB-4C1B-BD41-6655D3F9E902
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elisa Cordero
@ast
Elisa Cordero
@en
Elisa Cordero
@es
Elisa Cordero
@nl
Elisa Cordero
@sl
type
label
Elisa Cordero
@ast
Elisa Cordero
@en
Elisa Cordero
@es
Elisa Cordero
@nl
Elisa Cordero
@sl
prefLabel
Elisa Cordero
@ast
Elisa Cordero
@en
Elisa Cordero
@es
Elisa Cordero
@nl
Elisa Cordero
@sl
P1053
C-7797-2015
P106
P21
P31
P3829
P496
0000-0001-7766-7266